Skip to main content
. Author manuscript; available in PMC: 2022 Feb 2.
Published in final edited form as: Nat Cancer. 2020 Jan 13;1(1):59–74. doi: 10.1038/s43018-019-0010-1

Extended Data Fig. 4 |. Mutational Characteristics of the MSK clinical IMPACT cohort.

Extended Data Fig. 4 |

(a) Oncoprint illustrating somatic alterations of chromatin modifier genes, RB7 and MYC amplification in 617 PDAC cases including 26 ASCsand 51 PDACs with potential SF/SD. P-value was tested using two-sided Fisher’s exact test. * indicates P-value if analysis is confined to driver gene mutations only, (b) Entotic CIC are more frequent occur in TP53 mutant PDACs (n = 180) than in TP53 wild type PDACs (n = 42) (P = 0.021, Mann-Whitney U test, two-sided).